Program and book of abstracts 1st conference

October 17 th – 20 th , 2022, Congress Centre of Slovak Academy of Sciences, Smolenice castle, Slovakia

< 6L/min by the cannula received a flow of 1 L/min of a medical grade mixture of [3.6% H2; 96.4% N2] prepared by AirProducts (Spain). RESULTS: 700 patients were included for HydroCovid. No statistically significant difference was found on the Primary Endpoint between the intervention and placebo arms (46% of complications versus 44%). 12 patients were included for H2-Covid. Exposure Duration Limiting Toxicity was proven to be at least 6 days. Very encouraging results were observed, with very unusual sharp decrease of inflammatory markers such as CRP or of abnormalities of pulmonary CT. CONCLUSIONS: HRW at the dose of 2 x 250 mL/day did not reduce immediate complications of ambulatory Covid patients. Long-term follow-up is on-going, to explore potential impact on long-Covid. Our protocol of H2 inhalation is safe and can be used for further clinical trials for moderate Covid patients requiring oxygen-therapy, with very encouraging clinical results. ACKNOWLEDGEMENTS: we thank Drink HRW (donation of the Mg tablets + grant), AirProducts (donation of the medical gas + specific gas distribution equipment) and individual donators who supported HydroCovid by donations to Univ. Grenoble Alpes Foundation.

31